Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Authors

Showing 4 results for author "Ali Turunc".

Back to authors

Thumbnail for Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Non-Responder CAR-T Infusion Products

ABCL - 910

Ribosomal Stoichiometric Reprogramming and Integrated Stress Response Activation Define a Translational Stalling State in DLBCL Non-Responder CAR-T Infusion Products

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Metabolic Autonomy of Cytotoxic Programs Distinguishes Responder from Non-Responder CAR-T Effectors in DLBCL: A Single-Cell Co-Expression Network Analysis

ABCL - 914

Metabolic Autonomy of Cytotoxic Programs Distinguishes Responder from Non-Responder CAR-T Effectors in DLBCL: A Single-Cell Co-Expression Network Analysis

Ali Turunc

Poster Presenter: Ali Turunc

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Outcomes of Ruxolitinib in Adult Patients with Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation: A Propensity Score-Matched Real-World Analysis

ALL - 912

Outcomes of Ruxolitinib in Adult Patients with Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Cell Transplantation: A Propensity Score-Matched Real-World Analysis

Ali Turunc

Poster Presenter: Ali Turunc

Thumbnail for Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

CML - 913

Asciminib vs Dasatinib/Nilotinib as First-Line Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: A Propensity Score-Matched Analysis of Disease Progression and Safety Outcomes

Ali Turunc

Poster Presenter: Ali Turunc

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors